TD Waterhouse Canada Inc. Sells 18,281 Shares of Amgen Inc. $AMGN

TD Waterhouse Canada Inc. decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 15.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 103,282 shares of the medical research company’s stock after selling 18,281 shares during the period. TD Waterhouse Canada Inc.’s holdings in Amgen were worth $37,322,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Norges Bank bought a new position in Amgen in the 4th quarter valued at $2,164,162,000. Bank of America Corp DE bought a new stake in shares of Amgen during the second quarter worth $1,831,903,000. Capital World Investors grew its holdings in shares of Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Amgen by 1,102.7% in the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock valued at $993,031,000 after buying an additional 2,514,254 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after buying an additional 2,261,544 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Royal Bank Of Canada increased their price objective on shares of Amgen from $370.00 to $400.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Oppenheimer raised their target price on shares of Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Bank of America boosted their price target on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. Canaccord Genuity Group increased their price objective on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Finally, Guggenheim raised their price objective on shares of Amgen from $343.00 to $388.00 and gave the company a “neutral” rating in a research note on Monday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $381.68.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Nancy Grygiel sold 2,970 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 over the last ninety days. 0.85% of the stock is currently owned by insiders.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Repatha data could expand its addressable market. Amgen reported that Repatha reduced all-cause mortality by 20% in a prespecified analysis of the Phase 3 VESALIUS-CV trial, which studied more than 12,000 high-risk adults who had not previously experienced a heart attack or stroke. Earlier use could support broader adoption of the cardiovascular drug. Amgen Repatha VESALIUS-CV article
• Positive Sentiment: MariTide retains a potential convenience advantage in obesity treatment. Amgen’s investigational therapy could require less-frequent dosing than competing treatments from Eli Lilly and Novo Nordisk. That feature may help differentiate MariTide if its clinical and regulatory profile supports approval, although competition in the market remains intense. Amgen MariTide obesity article
• Neutral Sentiment: Shares had recently approached a 52-week high. Recent strength followed better-than-expected quarterly earnings and raised 2026 guidance, but the stock’s elevated valuation and gains left it more vulnerable to profit-taking when adverse regulatory news emerged. Amgen stock and 2026 guidance article
• Negative Sentiment: U.K. action against Tavneos intensified regulatory risk. The U.K. regulator suspended Tavneos for new patients and indicated a path toward revoking its authorization in March 2027, saying the drug’s benefit-risk balance was no longer favorable and that its pivotal efficacy study could not be relied upon. This compounds the FDA’s April proposal to withdraw U.S. approval over effectiveness, application-disclosure and liver-safety concerns, raising the possibility of broader loss of value for the drug. Amgen Tavneos regulatory pressure article
• Negative Sentiment: Insider selling added a modest sentiment headwind. Reported insider transactions showed seven sales and no purchases over the past six months, though these trades are less significant than the Tavneos developments. Amgen trading disclosures article

Amgen Stock Down 1.6%

Amgen stock opened at $437.23 on Friday. The firm has a market capitalization of $236.38 billion, a price-to-earnings ratio of 27.17, a PEG ratio of 3.20 and a beta of 0.43. The company’s 50 day simple moving average is $397.39 and its 200 day simple moving average is $367.15. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $447.03.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the firm posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 22.97 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen’s dividend payout ratio is currently 62.65%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.